Phaseline

Companies › Peptomyc

Peptomyc: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OMO-103
Myc inhibitor
MYCPhase 1Metastatic Pancreatic Cancer; Osteosarcoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06059001OMO-103Phase 1Metastatic Pancreatic CancerOncologyMay 2026
NCT06650514OMO-103Phase 2OsteosarcomaOncologyDec 2026

Targets

MYC (1)

Companies with the same targets

IDP Discovery Pharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.